Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster

Executive Summary

With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.

Advertisement

Related Content

EMA Defines Actions For Using CAR-T Registries For Regulatory Evaluation
Keep Us In The Loop: EMA Clarifies Expectations Following PRIME Kick-Off Meetings
EU CAR-T Race Tightens After Yescarta Reverts To Standard Review
PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy
EMA’s PRIME A Year On: Hits And Misses When It Comes To Applications

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel